Phase 2 Study of TD-9855 to Treat Fibromyalgia

Summary

The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.

Timeline

Start

2012-11

Primary completion

2014-01

Completion

2014-04

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs TD-9855 Group 2; p = 0.0277; Mean Difference (Final Values) -0.47; ANCOVA NCT01693692 ↗

Publications

• Kanodia J, Lo A, Baldwin RM, Graham RA, Bourdet DL. Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain. Clin Pharmacokinet. 2021 Jan;60(1):121-131. doi: 10.1007/s40262-020-00918-7.

Drugs

Indications